MedPath

Comparing Treatment out come of psoriasis with Oral Methotraxate versus Oral Tofacitinib

Phase 4
Conditions
Health Condition 1: L400- Psoriasis vulgaris
Registration Number
CTRI/2024/08/072427
Lead Sponsor
Rishana
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Chronic plaque psoriasis with PASI more than 10.

Patient with nail psoriasis.

Patient with Psoriatic arthritis.

Exclusion Criteria

Pregnancy and lactation.

Females and males who were planning to have a child and not willing for using contraception.

Systemic therapy taken for psoriasis in the past 4 weeks before enrolling into the study.

Topical therapy taken for psoriasis in past 2 weeks before enrolling into the study.

Acute or chronic liver disease or renal disease/ uncontrolled hypertension/ uncontrolled Diabetes mellitus.

known allergy to any of the study drugs.

Active infection such as Tuberculosis, HIV, Hepatitis B and C.

History of disseminated herpes zoster or herpes simplex or recurrent localized dermatomal herpes zoster.

Patient on any other immunosuppressants.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
PASI50 <br/ ><br>PASI75 <br/ ><br>PASI90 <br/ ><br>NAPSI <br/ ><br>ACR20 <br/ ><br>ACR50 <br/ ><br>ACR70Timepoint: 0,4TH,8TH,12TH,16TH,20TH WEEK
Secondary Outcome Measures
NameTimeMethod
PATIENT SATISFACTION SCORE <br/ ><br>PHYSICIAN GLOBAL ASSESSMENT SCORETimepoint: 20TH WEEK
© Copyright 2025. All Rights Reserved by MedPath